News – PULMONARY HYPERTENSION

Alaunos Therapeutics has bought Velaris Therapeutics, which is developing four biological drugs for pulmonary arterial hypertension (PAH) and related heart and lung diseases, October 13, 2026

The pipeline VLR199 (the lead candidate): works in the same way as sotatercept (Winrevair), by trapping proteins of the activin family that drive the abnormal growth of cells in the lung vessels. The aim is to improve on aspects of sotatercept that may not be “fully optimised”. First clinical results showing whether it works are […]

Alaunos Therapeutics has bought Velaris Therapeutics, which is developing four biological drugs for pulmonary arterial hypertension (PAH) and related heart and lung diseases, October 13, 2026 Read Post »

Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM), September 3, 2026

Pulnovo Medical‘s PADN-HF-PH trial results were presented at European Society of Cardiology (ESC) Congress 2026 in Munich, Germany, and published simultaneously in a New England Journal of Medicine article. The multicenter, randomized trial enrolled 264 patients with pulmonary hypertension associated with left heart disease (pulmonary hypertension associated with left heart disease (PH-LHD), World Health Organisation

Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM), September 3, 2026 Read Post »

Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026

Tenax Therapeutics, Inc. announced today the topline results of its Phase 3 LEVEL trial, which evaluated TNX-103 (oral levosimendan) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), Group 2 of the World Health Organisation (WHO) pulmonary hypertension classification. The trial did not meet its primary endpoint — improvement in

Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026 Read Post »

Phase 2 trial on new investigational treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) completes enrolment, Pulmonary Hypertension News, June 15, 2026

Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) is classified as Group 2 pulmonary hypertension by the World Health Organization (WHO). It is a type of heart failure in which the heart still pumps normally but becomes too stiff to fill properly with blood between heartbeats. This can cause pressure to build

Phase 2 trial on new investigational treatment for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF) completes enrolment, Pulmonary Hypertension News, June 15, 2026 Read Post »

Tenax Therapeutics reports progress on an investigational drug for World Health Organisation Group 2 pulmonary hypertension, BioSpace, May 12, 2026

Tenax Therapeutics has reported good progress on their Phase 3 LEVEL study investigating TNX-103, a therapy for PH-HFpEF – pulmonary hypertension associated with heart failure with preserved ejection fraction, Group 2 of the World Health Organisation, WHO, classification. Topline data expected in the third quarter of 2026, and enrolment is also advancing in LEVEL-2, a

Tenax Therapeutics reports progress on an investigational drug for World Health Organisation Group 2 pulmonary hypertension, BioSpace, May 12, 2026 Read Post »

Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026

Pulnovo Medical, a Shanghai-based company developing therapies for pulmonary hypertension and heart failure, has raised $100 million in a strategic financing round led by Medtronic, which has also entered into a separate commercial agreement with the company exploring future commercialisation opportunities. Pulnovo’s flagship product is the Pulmonary Artery Denervation (PADN) System, a minimally invasive device

Pulnovo Medical and Medtronic Join Forces to Advance Pulmonary Artery Denervation for Pulmonary Hypertension, Pulse 2.0, April 25, 2026 Read Post »

Tenax Therapeutics extends long-term study of oral levosimendan (TNX-103) in pulmonary hypertension with preserved ejection fraction (HFpEF) patients, February 2026

Tenax Therapeutics is conducting a long-term open-label extension study of TNX-103, an oral formulation of levosimendan, in patients with pulmonary hypertension associated with heart failure and preserved Ejection Fraction (HFpEF), Group 2 of the World Health Organisation classification. In its intravenous form TNX-103 is a drug authorized for use in 60 countries for acute decompensated

Tenax Therapeutics extends long-term study of oral levosimendan (TNX-103) in pulmonary hypertension with preserved ejection fraction (HFpEF) patients, February 2026 Read Post »

Winrevair (sotatercept) meets primary endpoint in Phase 2 CADENCE study on patients with a subset of pulmonary hypertension due to left heart disease (PH-LHD), November 18, 2025

Combined post- and precapillary pulmonary hypertension (CpcPH) represents a subset of pulmonary hypertension due to left heart disease (PH-LHD), also known as World Health Organisation Group 2 pulmonary hypertension. There are currently no treatments specifically approved for this condition. The CADENCE met its primary endpoint, showing a statistically significant and clinically meaningful reduction in pulmonary

Winrevair (sotatercept) meets primary endpoint in Phase 2 CADENCE study on patients with a subset of pulmonary hypertension due to left heart disease (PH-LHD), November 18, 2025 Read Post »